Zobrazeno 1 - 10
of 71
pro vyhledávání: '"Peter J Kushner"'
Autor:
Alison D Parisian, Leslie Hodges-Gallagher, Richard Sun, Susanna Barratt, Gopinath S Palanisamy, Julia Lawrence, Pamela Klein, David C Myles, Cyrus L Harmon, Peter J Kushner
Publikováno v:
Cancer Research. 82:P5-08
The human epidermal growth factor receptor 2 (HER2, also known as ERBB2) oncogene is overexpressed in approximately 25% of breast cancer tumors and is associated with a high rate of brain metastasis. Patients with brain metastases have a poor prognos
Autor:
Alison D. Parisian, Caitlin Miller, Fabian Ortega, Leslie Hodges-Gallagher, Susanna Barratt, Joey Azofeifa, Peter J. Kushner, David Kulp, Cyrus L. Harmon
Publikováno v:
Cancer Research. 82:5375-5375
OP-1250 is an orally-bioavailable complete estrogen receptor antagonist (CERAN) previously shown to shrink wild-type and Y537S mutant estrogen receptor-positive (ER+) tumors in multiple preclinical xenograft models. To better understand the effects o
Autor:
Muriel Laine, Marianne E. Greene, Tiffany Leng, Sophia Li, Gopinath S. Palanisamy, Cyrus L. Harmon, Leslie Hodges-Gallagher, Peter J. Kushner, Geoffrey L. Greene
Publikováno v:
Cancer Research. 82:1618-1618
Estrogen receptor positive (ER+) breast cancers represent about 70-75% of all breast cancer. In general, these cancers are effectively treated with adjuvant endocrine therapies, with or without the addition of CDK4/6 inhibitors. However, many patient
Autor:
Pamela M. Klein, Alison D. Parisian, Leslie Hodges-Gallagher, Richard Sun, Peter J. Kushner, David C. Myles, Cyrus L. Harmon
Publikováno v:
Cancer Research. 81:LB122-LB122
Estrogen receptor-positive (ER+) breast cancer can undergo metastatic spread to the brain, which occurs in up to 15% of HER2-/ER+ metastatic breast cancer patients. Although endocrine therapy is not explicitly approved for brain metastasis and clinic
Autor:
Manish Patel, Peter J. Kushner, Cyrus L. Harmon, Pamela M. Klein, Carlos Alemany, Trinh Le, Jo Anne Zujewski, Erika Hamilton, Nan Lin
Publikováno v:
Cancer Research. 81:OT-09
Background: Endocrine therapy has been the primary treatment modality for HR+, HER2- metastatic breast cancer (MBC). Endocrine agents are administered sequentially, either in combination with targeted therapy or as monotherapy. The majority of patien
Autor:
Pamela M. Klein, Peter J. Kushner, David C. Myles, Richard Sun, Leslie Hodges-Gallagher, Jo Anne Zujewski, Cyrus L. Harmon
Publikováno v:
Cancer Research. 81:PS18-16
Antiestrogens are widely used to treat ER+, HER2- breast cancer however these may produce estrogen-like agonist effects in a cell and gene-specific manner. Furthermore, this partial agonism has been implicated in the development of tumor resistance.
Publikováno v:
Cancer Research. 80:4376-4376
Fulvestrant (FASLODEX), a Complete Estrogen Receptor ANtagonist (CERAN) is recognized as the most effective endocrine therapy for estrogen receptor positive (ER+) metastatic breast cancer. Unfortunately, fulvestrant must be injected i.m. and has poor
Publikováno v:
Cancer Research. 80:P5-05
Fulvestrant (FASLODEX) is the most effective endocrine therapy for estrogen receptor positive (ER+) metastatic breast cancer (MBC). Despite this superiority, fulvestrant must be delivered by intramuscular injection and its efficacy appears limited by
Autor:
Leslie Hodges-Gallagher, David C. Myles, C.E. Fowler, Geoffrey L. Greene, R. Sun, Isaac N. Plant, Bradley Green, Cyrus L. Harmon, Sean W. Fanning, Peter J. Kushner
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-12 (2018)
Complex tissue-specific and cell-specific signaling by the estrogen receptor (ER) frequently leads to the development of resistance to endocrine therapy for breast cancer. Pure ER antagonists, which completely lack tissue-specific agonist activity, h
Autor:
Ira D. Goldfine, Betty A. Maddux, John A. Kerner, Michael J. Campbell, Marianna Zavodovskaya, Jack F. Youngren, Leslie Hodges, Geoffrey Allan, Peter J. Kushner, Laura Shiry
Publikováno v:
Journal of Cellular Biochemistry. 103:624-635
We have reported that nordihydroguaiaretic acid (NDGA) inhibits the tyrosine kinase activities of the IGF-1 receptor (IGF-1R) and the HER2 receptor in breast cancer cells. Herein, we studied the effects of NDGA on the growth of estrogen receptor (ER)